The Old-Order Amish have low rates of vaccination and are at increased risk for vaccine-preventable diseases. A written survey was mailed to all Amish households in the largest Amish community in Illinois inquiring about their vaccination status and that of their children.
D escendants of the Swiss Anabaptists, the Old-Order Amish (hereafter referred to as Amish) are the most distinctive of all Amish sects, relying on traditional beliefs and practices and rejecting as worldly the majority of modern conveniences. Because of a birth rate of approximately 7 children per family and a 90% retention rate for its youth, the Amish population in the United States has increased from 8200 in the early 1900s to approximately 180,000 now. 1 In Illinois, the largest Amish community is centered around the town of Arthur in the east-central region of the state. Eight additional smaller communities are located throughout central and southern Illinois. Amish genealogic records from the year 2003 list 4538 persons living in these 9 communities; 3431 (76%) of these persons resided in the Arthur community, which consists of 775 households, including 374 households with children aged Ͻ15 years. 2 Amish views on health and health care might contribute to their lack of adoption of vaccination as a means of disease prevention. Health is considered a gift from God and is not solely the result of preventive behaviors or medical intervention. 1 Vaccination is not prohibited by the church; however, it is often not encouraged either. Additionally, Amish consciously avoid dependence on government assistance and might consider acceptance of free vaccinations a form of government welfare.
Multiple studies in the context of outbreaks of vaccinepreventable diseases have made a direct link between the low rate of reported vaccine coverage in Amish communities and their susceptibility to disease outbreaks. Outbreaks of rubella, 3 measles, 4 pertussis, 5 Haemophilus influenzae, 6 and polio, 7 as well as increased cases of childhood tetanus, 8 have disproportionately affected Amish communities in the United States. In each of these outbreaks, the vaccination rates were too low to confer herd immunity to the Amish communities, which provided the opportunity for vaccine-preventable diseases to spread largely unchecked among community members and placed vulnerable members of the surrounding community at risk for contracting these diseases. Unvaccinated Amish communities can serve as environments where vaccine-preventable diseases persist, putting unvaccinated persons at risk for illness and slowing progress towards national goals of elimination of vaccine-preventable diseases.
No data exist on vaccination beliefs and practices among the Amish in Illinois. We initiated this study to quantify the proportion of Amish households that reject vaccination and determine how often this rejection is due to religious beliefs.
MATERIALS AND METHODS
In September 2005, questionnaires were mailed to all Amish households in the Arthur community through a community newsletter. To ensure that the questionnaire was culturally sensitive and understandable, Amish community leaders were consulted on appropriate study content and methodology before distribution. The questionnaire asked about the respondent's vaccination status and that of all children aged Ͻ15 years residing in the household, where they had received vaccinations, and if applicable, reasons for not receiving vaccinations. Factors that might influence vaccination use (eg, the age of parents and frequency of nonemergency medical care) were also included in the questionnaire. Households without children only answered demographic and personal vaccination history questions. The questionnaires were returned to the Illinois Department of Public Health in prepaid envelopes, with no identifying information provided by the respondents. Univariate analysis was performed by using EpiInfo, version 3.3.2, statistical software (Centers for Disease Control and Prevention, Atlanta, GA) in which odds ratios (ORs) were calculated and hypotheses tested by using the 2 test. ORs with 95% confidence intervals (CIs) that excluded 1.0, and P values Ͻ.05 were considered statistically significant.
RESULTS
Responses were received by 225 (60%) of the 374 Amish households in the community with children aged Ͻ15 years. An additional 120 responses were received by households without children. A total of 189 (84%) households with children reported that all of their children had received vaccinations; 28 (12%) reported that some of their children had received vaccinations; and 8 (4%) reported that none of their children had received vaccinations. Among the 36 respondents who had unvaccinated children, 16 (44%) cited concerns about vaccine safety as the reason their children were unvaccinated; 3 (8%) attributed their children's unvaccinated status to religious objections (Table 1) . Not having received vaccinations as a child (OR, 4.2; 95% CI, 1.1-16.3) and seeking nonemergency medical care Յ2 times during the preceding year (OR, 2.6; 95% CI, 1.1-6.0) were statistically associated with having unvaccinated children. Decisions about children's medical care were made by fathers in 6 households (3%), were made by mothers in 29 households (13%), and were made jointly in 188 households (84%). Approximately three quarters (74%) of respondents had gone to the doctor's office to receive vaccinations.
Among all respondents who knew their own vaccination status, 281/313 (90%) reported that they had received vaccinations as children. Stratified analysis revealed that younger respondents were statistically significantly more likely to have been vaccinated as children; 194/202 (96%) respondents aged Ͻ45 years had received vaccinations, whereas 87/111 (78%) respondents aged Ն45 years had been vaccinated (OR, 6.7; 95% CI, 2.7-16.9; P Ͻ 0.0001). The majority of respondents (93%) were uninsured, and the majority of those without insurance (71%) relied on a mutual aid network to assist with medical expenses.
DISCUSSION
This study reveals that Amish households do not universally reject vaccines, and Amish objections to vaccines are not typically for religious reasons. Additionally, the decision to accept vaccinations is based on multiple factors and might be influenced by information on vaccine safety provided by trusted medical providers. These data demonstrate that previous reports of Amish vaccination status derived from previous studies should not be generalized to all Amish communities.
The study finding that 90% of respondents had received vaccinations and 84% of families had vaccinated all of their children was surprising, on the basis of our past understanding of Amish vaccination rates. No comprehensive study has examined vaccination coverage among Amish in the United States. Common methods of assessing vaccination status (eg, telephone surveys 9 or college entry surveys) lack the ability to include the Amish as part of the study population because the Amish do not have telephones or attend college. Small communitybased surveys of Amish in Pennsylvania 1,6 and Wisconsin 10 demonstrated that the vaccination rates of children in these Amish communities were too low to prevent vaccine-preventable diseases, if introduced, from spreading within the community. This study demonstrates that previous reports of Amish vaccination status should not be generalized to all Amish communities.
The higher rate of vaccination among young adults in our study demonstrates that adoption of vaccination in this community has increased over time. Although the reasons for this increase are not entirely clear, this finding demonstrates that Amish beliefs and practices regarding vaccination are not static and can be influenced by factors in the community.
The objections to vaccinations expressed in this survey indicate that Amish concerns about vaccines are similar to those expressed by other parents of unvaccinated children. Amish parents of unvaccinated children cited objections to vaccines based on concern for their children's well-being rather than objections based on theological, ideological, or philosophic reasons, supporting previous findings that religious objection is not the primary reason for rejecting vaccinations. 1, 6 Safety concerns were the most frequently listed reason for not vaccinating, replicating findings from nationwide surveys 9 of non-Amish parents of unvaccinated children. These important concerns, when understood, can be addressed by medical providers.
The Amish rely on trusted health-care providers for information about preventive practices. 1 The study finding that the overwhelming majority of households visit their physicians for vaccinations underscores the importance of the doctor-patient relationship in influencing their decision to vaccinate their children. Additionally, because the majority of Amish families do not have insurance coverage for vaccinations, the fact that the majority qualify for the Vaccines for Children Program makes obtaining vaccinations at their doctor's office economically feasible. These visits provide an important opportunity for the health-care provider to ask about the vaccination status of all eligible children.
Although Amish society is often considered patriarchal, this study revealed that, in the majority of households, the mother is considered to have a joint role in making decisions about their children's medical care. This fact is important to consider when developing educational messages for Amish communities.
Study limitations include a moderate response rate, the lack of ability to correlate survey response with vaccine registry data, and the lack of detailed vaccination information for each child.
The vaccination rate reported in this study has critical implications for efforts to promote vaccinations among Amish communities. The results of this study indicate that Amish communities might be influenced to accept vaccines if medical providers openly address the topic of vaccination with Amish patients and deal with individual concerns about vaccination. We recommend that federal, state, or local health agencies create culturally sensitive educational materials that specifically address vaccine safety and make these materials available to Amish patients through their health-care providers. These findings provide hope that improved vaccination coverage among Amish communities can be achieved through building relationships and targeted public health efforts.
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Neither of the authors has a commercial or other association with products or processes that might pose a conflict of interest. No grants or other outside funding sources were used in the collection of these data. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. W hile adults constitute the majority of travelers to tropical and subtropical countries, the number of children who travel abroad is constantly growing. Young children rarely travel on their own and typically have little to no role in trip planning. The travel conditions of children and of those who travel with children are likely to be quite different from those of adults traveling without children. These differences in travel style may present different risk factors of acquiring disease while abroad. In a study of travel-related hepatitis A (HA) in both children and adults, we compared the characteristics of the trips during which they acquired their disease, to identify particular risk factors for children.
METHODS
As part of study evaluating the risk of HA in travelers, 1 all laboratory-confirmed, travel-related HA cases reported in Quebec and Ontario, Canada, with onset between January 1997 and November 1999, were eligible. Cases were identified from the provincial notifiable disease databases. Telephone interviews were performed between November 1999 and May 2000 to obtain information regarding the trip during which cases acquired their disease. 1 Trips were categorized into 4 levels of risk as follows: "low risk" included travel for 2 weeks or less, with all nights spent in first-class hotels, "visiting friends and relatives" (VFR) included trips during which more than half of the nights were spent in the homes of friends or relatives, "high-risk" travel was defined as that lasting Ն4 weeks, with Ն50% of the nights spent in low-budget hotels. All other trips were included in the "intermediate-risk" group. Age was divided in 10-year categories, and cases less than 20 years old were considered children.
RESULTS
A total of 315 travel-associated HA cases were reported in Quebec (n ϭ 135) and Ontario (n ϭ 180) during the study period. Interviews were completed for 69% (84/121) of the children and 51% (99/194) of the adult cases. Among the 183 study participants, there were 46% children and 54% adults. Participation rate was 64% in Quebec (67% in children and 62% in adults) and 54% in Ontario (71% in children and 41% in adults). Only a few eligible cases (n ϭ 13) refused to participate in the study. Most of nonrespondents were people who could not be contacted despite 6 to 10 attempts at different times. The proportion of male cases was similar in children and adults: 51% and 49%, respectively. There was a significant increase in household income with the age of cases (P Ͻ 0.001).
Twenty-two percent of cases were younger than 10 years old, 24% aged 10 -19, 20% aged 20 -29, 16% aged 30 -39, 12% aged 40 -49, 3% aged 50 -59 and 3% were aged Ն60 ( Table 1 ). Most cases aged Ͻ20 years had traveled in Asia (57%), mainly to Pakistan (30%) or India (17%), whereas 68% of adult cases had traveled to Latin America or the Caribbean, mainly Mexico (32%) or the Dominican Republic (10%). Overall, children traveled for longer periods than did adults (P Ͻ 0.0001) and there was a significant trend of decreasing duration of travel with older age (P Ͻ 0.0001). The median duration of trips among children was 42 days compared with 14 days in adults. While 60% of children traveled for more than 30 days, only 28% of adults did.
The proportions of cases in each travel risk level varied significantly with age (P Ͻ 0.0001). Overall, only 6% of cases had taken a trip classified as "high risk," and more than half (55%) had visited friends and relatives. The proportion VFR decreased significantly with age. Only 29% of adults visited friends and relatives while staying abroad, whereas 85% of children did. Children were also more likely to eat Ն50% of their meals in the homes of friends and relatives than adults (85% versus 33%, respectively; P Ͻ 0.0001). Among children VFR, 63% had traveled to countries in which they had not been born. The self-assessed attitude toward hygiene during trips did not significantly vary with age. Using gastroenteritis as a proxy for unsafe behaviors for enteric diseases, children and adults were affected equally (37% versus 37%). Overall, only 4% of the HA cases reported having visited a travel clinic before departure, a proportion that was similar among children and adults.
Nearly a quarter (23%) of reported cases occurred among individuals born in a HA endemic country (Table 1 ) (Countries where Hepatitis A is Endemic-listed in Online Only Appendix). The majority of cases among those born in a nonendemic country (including Canada) had visited Latin America or the Caribbean (59%), mainly Mexico (25%) or the Dominican Republic (9%). In contrast, the majority of cases among those born in a HA endemic country had visited Asia (65%), mainly Pakistan (26%) or the Philippines (14%). Travelers born in an endemic country who acquired HA stayed abroad for a longer period than those born in nonendemic countries (35 versus 21 days, P ϭ 0.004) and traveled more frequently for Ͼ30 days (53% versus 39%). Almost all (93%) of the cases born in HA endemic countries visited friends and relatives (79% in their native country and 14% in other countries) compared with 43% of individuals born in a nonendemic country. Similarly, travelers born in an endemic country were more likely to eat more than half their meals in the homes of friends and relatives than other travelers (91% versus 46%, P Ͻ 0.0001). Individuals born in HA endemic countries were less aware of the health risks related to travel in a HA endemic country than were other travelers (26% versus 43%, P ϭ 0.04).
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DISCUSSION
Our results indicate that approximately half of the reported travel-associated HA cases occur among children. Most pediatric cases had traveled in Asia for more than 30 days and had stayed and eaten most of their meals in the homes of friends and relatives in a country where they had not been born. Adult cases, on the other hand, had visited Latin America or the Caribbean for 14 days or less and had stayed primarily in low-or moderate-risk establishments. Although the slightly higher participation rate among children than adults may have overrepresented pediatric cases of HA in our series, the greater frequency of asymptomatic HA infection among children would have the opposite effect. 2 Given that HA cases in children were nearly as numerous as in adults, whereas most international travelers are adults, our results suggest that the incidence of HA infection is higher among traveling children than in adults.
Our results also show that individuals who were born in a HA endemic country accounted for nearly a quarter of the reported cases. In contrast to HA-infected travelers born in a nonendemic areas who most frequently took short trips to Latin America or the Caribbean and stayed in first-class hotel (low risk), HA-infected travelers born in endemic countries had typically visited Asia for 30 days or more, where they had visited friends and relatives. Given the rapid increases in immigration from the developing world in the last 2-3 decades and the general decrease in transportation costs, it is reasonable to anticipate steady growth in the total number of foreign-born Canadians who will take trips with the latter characteristics. The scenario of the immigrant family returning to their country of origin with their young children born in the developed world is very common. In our series, 5 families who visited friends and relatives had 2 of their children infected with HA during the same trip, one family had 4, and other had only 1. The majority (68%) of their children were born in developed countries. Although remarkably few such families present to travel clinics before departure, when they do, the parents are invariably most concerned about preventative vaccines for their children.
Our results show that adults returning to their native country are also at elevated risk for endemic diseases, including HA. In our series, adult cases born in endemic countries immigrated to Canada at a median age of 19 years (range, 2-34). Clearly, having lived in an endemic country for many years does not necessarily prevent immigrant travelers from HA.
Our study has limitations. First, all cases were identified through notifiable diseases databases and were eligible if they reported having visited a HA endemic area in the 6 weeks before onset of symptoms. Failure to detect the disease is very likely to have occurred among asymptomatic or mildly symptomatic cases and cases treated abroad. Second, given the retrospective nature of the study, the data collected may have been subject to a certain degree of recall bias. Because the self-classification of lodging facilities or restaurants was subjective, there is a possibility of misclassification between the types of establishments and food premises. Last, because the countries of origin of immigrants is different between Canada and other countries, this will change the destination of VFR trips. 3 Nevertheless, these limitations are unlikely to change the main observations that trips taken by children are different from those of adults and trips taken by individuals born in HA endemic countries differ from those taken by other travelers in several important respects, including destination, duration and travel style.
In conclusion, travel-acquired HA infection is not limited to adult travelers, and traveling children are at particular risk. Because traveling children rarely arrange their itineraries or housing and eating arrangements and because they are more likely than adults to visit friends and relatives, they may have great difficulty adhering to medical recommendations regarding food and water precautions, even if they are aware of the risks. These particular vulnerabilities of pediatric travelers need to be taken into consideration during pretravel consultation. 4 Similarly, specific recommendations should be given to adult travelers born in HA countries to reduce their risk. Because very few adults and children visit a travel clinic before departure, population-based intervention may need to be implemented to reach the majority of travelers to reduce the burden of travel-related HA.
I nvasive fungal infections are an important cause of morbidity and mortality, especially in patients with hematologic malignancy. Despite the availability of new drugs and more aggressive therapeutic strategies, mortality rates in immunocompromised patients remain extremely high. 1 Caspofungin is the first of a new class of antifungals (echinocandins) that inhibit the synthesis of the 1,3-beta-D-glycan, an essential cellswall polysaccharide. 2 Caspofungin is fungicidal against Candida species, even those resistant to fluconazole including C. kruzei and C. glabrata and efficacious against a broad spectrum of fungi, including all Aspergillus species. Moreover, its original mechanism of action warrants the association of caspofungin in patients who are refractory to the other antifungal therapies. It does not require special precaution in adults, nor dosage adjustment according to renal or liver function. Together with its good safety profile in adults, the product characteristics provide good arguments for salvage therapy in the pediatric population with invasive fungal infections.
Few reports have addressed the use of caspofungin in children with documented invasive fungal infections. In the Franklin et al 3 study, only 13 patients had documented infections; the others were treated empirically; and Odio et al 4 reported salvage treatment in a series of 10 neonates. We report on 20 children with proven or probable invasive fungal infection who received caspofungin, either alone or as an add-on therapy during the Compassionate Use French Program before the product was approved. Their records were reviewed and analyzed for efficacy and safety of the drug.
PATIENTS AND METHODS
Patient's records were reviewed to identify patients diagnosed with a probable or proven invasive fungal infection and who had received at least 7 days of caspofungin treatment as part of the French Compassionate Use program between July 2001 and June 2003. Critically ill patients who received caspofungin during less than 7 days were not evaluable and, therefore, were excluded from the study. Informed consent was obtained from all patients' parents before caspofungin administration.
A retrospective chart review was performed from those 20 patients being managed in 1 intensive care and 6 transplantation units in France. Patients' demographics (age, sex, weight) and history of the underlying disease were collected. Most attention was given to the description of the fungal infection, by its localizations, identification of the fungus, and classification as proven or probable infection, according to the consensus committee definition of the European Organization for Research and Treatment of Cancer/ Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. 5 All adverse events emerging during caspofungin treatment were collected. Complete and partial responses were classified as successful outcomes. Survival was assessed at day 7,
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The Sixteen patients had neutropenia (less than 500/L) in the 2 months before the diagnosis of fungal infection, with a mean duration of the aplastic phase of 27 days (median, 12; range, 0 -180 days). Five patients had undergone allogenic bone marrow transplantation, and 17 had received different courses of conventional chemotherapy. Eleven children had Aspergillus infections, proven in 4 cases, and probable for 7. Six of those 11 patients had localized pulmonary infection and the others, disseminated infections. Seven patients had documented candidiasis, 6 proven (6 disseminated infections by C. albicans ͓n ϭ 3͔, C. parapsilosis ͓n ϭ 1͔, C. glabrata ͓n ϭ 1͔, C. krusei ͓n ϭ 1͔) and 1 probable (1 pulmonary ͓C. albicans͔). Two patients had infection with Rhodotorula, 1 proven and 1 probable (1 disseminated and 1 pulmonary, respectively). The 2 patients with probable pulmonary yeast infections had both clinical infectious symptoms (fever and cough), radiologic abnormalities compatible with a fungal infection, and a yeast (C. albicans and Rhodotorula sp., respectively) on bronchoalveolar lavage fluid samples. Four patients had renal insufficiency resulting from amphotericin B or cyclosporine A therapy; 1 had a major dyslipemia and 1, a chronic liver graft-versus-host disease associated with a cholestasis and 3-to 5-fold increased liver enzymes. Drug Administration. Before caspofungin initiation, 13 patients had been treated with 1 or 2 antifungals: 9 with amphotericin B, 3 with fluconazole, 1 with voriconazole and 1 with flucytosine. Nine of these 13 patients received caspofungin because they were not responding (one as monotherapy, the other as combination) and 4 of 13 because they were intolerant to liposomal amphotericin B (one in monotherapy, others as combination). Seven patients received caspofungin as first-line therapy (5 as monotherapy, 2 as combined to other antifungal therapy͓ies͔).
Other concurrent antifungals were administered concomitantly to caspofungin to 14 of the patients: amphotericin B (n ϭ 8) and/or voriconazole (n ϭ 7) and/or fluconazole (n ϭ 2) and/or flucytosine (n ϭ 1).
Caspofungin was administered through a central venous infusion in all patients (1-hour infusion) except temporarily via peripheral access in 3 patients whose central venous catheter had been removed for a few days.
Out of the 12 patients weighing more than 45 kg, 10 received 70 mg on day 1, followed by 50 mg per day, and 2 received 50 mg per day from day 1 on. The other 8 patients received between 1 and 4 mg/kg/d, the daily average being 1.88 mg/kg (median, 1.40; range, 0.95-3.85 mg/kg). The mean duration of caspofungin administration was 54 days (median, 35; range, 7-280 days). The mean cumulative dose was 65 mg/kg (median, 34; range, 13-270 mg/kg).
Patients were also receiving other therapies for their malignancies, and 5 patients were receiving cyclosporine A.
RESULTS
Safety.
Forty-five treatment emergent adverse events (TEAEs) were observed in 15 patients and 11 adverse events considered as possibly drug related (DRAEs) were experienced by 9 patients, of WHO grades 1 to 3. None of the TEAEs led to caspofungin discontinuation.
One patient exhibited a livedo considered as possibly drug related, 2 patients complained of nausea and vomiting during the drug infusion. Six patients had elevated liver enzymes, 5 were mild and considered possibly drug related (one of them concomitantly receiving cyclosporine A); the sixth patient suffered from a hepatic graft-versus-host disease, with serum aminotransferases values more than 3 times the normal upper limit. Two patients had moderate hypokalemia; both were concomitantly receiving fluconazole. One patient had a peripheral venous thrombosis at the injection site; he was simultaneously treated with quinupristine/dalfopristine. Renal function of patients with renal insufficiency did not deteriorate. Efficacy. Overall survival is shown in Table 1 There were 6 deaths observed while patients were receiving caspofungin therapy; none of them was related to drug intolerance but either to the lack of treatment efficacy (uncontrolled invasive fungal infection in 5 patients) or to the underlying condition (1 patient).
For the 11 patients with aspergillosis, 8 patients exhibit a successful response: 3 were treated with monotherapy and 5 with an antifungal combination (caspofungin ϩ voriconazole). The final survival rate was 5 of 11 patients. Four patients died of their invasive fungal infections: 1 refractory patient who died at day 7 of adding on caspofungin to liposomal amphotericin B, 2 despite the concurrent administration of liposomal amphotericin B or voriconazole (both were in relapse of an AML), and 1 who had an initial partial response but died of the invasive fungal infections associated with a Gram-negative sepsis. Two patients died of other causes after caspofungin discontinuation once the invasive fungal infection was cured (one from a bilateral pneumothorax and the other from the leukemia relapse).
All the 7 patients but 1 in the candidiasis cohort received antifungal therapy in combination. The 3 patients who did not respond to treatment (caspofungin ϩ fluconazole in 2 patients, caspofungin ϩ amphotericin B in 1) were all infected by C. albicans, and 2 of them actually died of their invasive fungal infection. Two other patients did survive the candidiasis but died later of other events with no fungal infection, one from chronic GVH disease and the other from multiorgan failure after bone marrow transplantation. 
DISCUSSION
This study is the second largest report of the use of caspofungin in children as salvage therapy or first line treatment. 3 The overall 50% survival rate and 65% of complete response rate constitute an encouraging evidence of caspofungin efficacy in this pediatric population with invasive fungal infections. This study's main limitations are its small size (n ϭ 20) and retrospective nature which precludes the assessment of specific safety events.
Overall, the therapy was well tolerated and no major safety issues were seen, similar to reports of others. 6 -10 The most frequent DRAEs were fever, nausea and vomiting, hepatic enzyme elevation and hypokalemia, as observed in the current study, phlebitis (as reported in one patient simultaneously treated with another venotoxic product), and renal insufficiency not reported here. Out of the 5 patients receiving cyclosporine A, only 1 experienced elevated aminotransferases. The association is usually avoided because concomitant use has been associated with transient elevated aminotransferases; however, 2 recent retrospective studies seem to indicate that this adverse event does not occur in most cases. 11, 12 In terms of efficacy, we recognize that the sampled population is small and that many patients had received combination therapy with other antifungals. Results were excellent in patients receiving caspofungin as first-line therapy (75% CR and 75% survival) or as monotherapy (100% CR, 75% survival). This latter result could be explained by the fact that patients who received caspofungin as monotherapy had a less aggressive infection. Conversely, when employed as first-line therapy, caspofungin was most frequently associated with 1 or 2 other antifungals. Interestingly, the association of voriconazole ϩ caspofungin in aspergillosis gave an 80% response rate (60% survival), despite the lack of evidence of a potential in vitro synergy, but in accordance with animal data 13 and clinical case reports. 14 Whether this combination might have better chances of success than a combination of caspofungin ϩ liposomal amphotericin B, as observed for the salvage treatment of aspergillosis in patients with hematologic malignancies, 9 remains to be established by prospective randomized studies.
We found no relationship between the response and the localization of the invasive fungal infections (pulmonary or disseminated), its character (proven or probable), the age of the patients, the underlying condition or the administrated dosage. Recently, Walsh et al 15 emphasized that the dosage of 1 mg/kg/d led to a suboptimal product exposure in children. The comparable exposure to that of adult patients treated with 50 mg/d is reached by the administration of 50 mg/m 2 /d. Hence, 4 of 7 patients receiving less than 45 kg were at a suboptimal dose. Three had a complete response and survived, and 1 died of his aspergillosis. R espiratory syncytial virus (RSV) occurs in annual epidemics and is the leading cause of lower respiratory tract infections (LRTI) in infants and young children. Severe LRTI with considerable morbidity requiring hospitalization is found especially in young children with underlying clinical conditions. In addition, further predisposing environmental and demographic risk factors for severe RSV infection have been described: male sex, young age (Ͻ6 months), birth in the first half of the RSV season, crowding/siblings and daycare exposure. 1 Prophylaxis with palivizumab (Synagis) significantly reduces hospitalizations due to RSV (RSV-H) in preterm children. Due to the high cost of this prophylaxis, however, there is an ongoing discussion concerning which preterm children have the greatest benefit from palivizumab. We therefore evaluated risk factors for RSV-H in a large German-Austrian cohort of preterm children with a GA of 29 to 35 weeks.
METHODS
A cohort of 1236 preterm children with a GA of 29 to 35 weeks (ie, 29 ϩ 0 to 35 ϩ 6) was formed by pooling the Munich RSV-study cohort and the Austrian 29 -32 RSV-study cohort. Results from both studies have been previously published. 2, 3 The Munich RSV-study cohort consisted of 620 preterm children with a GA of 29 (29 ϩ 0) to 35 (35 ϩ 6) weeks who had been admitted to 9 neonatal intensive care units in Bavaria between November 1, 1998, and October 31, 1999.
The Austrian 29 -32 RSV-study cohort consisted of 616 preterm children with a GA of 29 (29 ϩ 0) to 32 (32 ϩ 6) weeks, born between June 1, 2001, and December 31, 2002, who had been admitted to 20 neonatal units in Austria.
Written informed consent was obtained from all parents or guardians of children included in these studies. One thousand one hundred fifty-eight children remained in the pooled cohort as 78 (6.3%) children were excluded because they had received palivizumab during the surveillance period. Medical discharge letters of all ARI-H during follow-up were analyzed for RSV-H. Only the child's first RSV-H was regarded. Definite RSV-H was assumed for all patients with ARI-H who had a positive RSV antigen test. Because RSV tests were not regularly performed in all hospitals, an additional clinical case definition for RSV-H was used: Children hospitalized between October and May with a clinical diagnosis of obstructive bronchitis, bronchiolitis, apnea or a diagnosis of pneumonia in the presence of wheezing were classified as suffering from a probable RSV infection. All analyses refer to the sum of laboratory-proven and probable clinical RSV-H during the first year of life. Children with suspected nosocomial RSV infection, who developed clinical respiratory symptoms or a positive RSV test after day 3 of hospitalization were excluded. Neurologic disorder was defined as the presence of 1 or more of the following diagnoses: intracranial hemorrhage (ICH) grade III or IV (periventricular hemorrhage), cystic periventricular leukomalacia (cPVL), cerebral infarction, hydrocephalus or other symptomatic neurologic conditions. Statistical Analyses. The cumulative incidence (or risk) of RSV-H/ ARI-H was calculated as the percentage of children admitted for RSV-H/ARI-H during the first year of life. Nonparametric compar-isons between groups were conducted with the 2 test or Fisher exact test, and continuous variables were compared using Student t-test. Univariate and multivariate logistic regression analyses were used to assess independent risk factors for RSV-H. We included variables with a level of statistical significance below 0.15 in the multivariate logistic regression model using the backward selection procedure. Based on a multivariate logistic regression model, the estimated risk of RSV-H was calculated by:
Differences between groups were considered to be significant if the P value of the statistical test was below 0.05. Statistical analyses were conducted with SAS, Release 8.02 (Cary, NC).
RESULTS
One hundred ten of 1158 children had an ARI-H (9.5%) and 57 (4.9%) children had a RSV-H during the follow-up period. Thirty-one of 57 children had a laboratory-proven RSV-H. Among the 26 of 57 children classified as probable RSV-H, 21 were not tested for RSV infection. Five children with only 1 test were tested negative but had a documented clinical diagnosis of RSV infection. Forty-eight children (4.2%) were hospitalized for RSV infection during the first year of life. Children from the Munich RSV-study were significantly more likely to be twins or triplets (P ϭ 0.02) than children from the Austrian study. In a stratified analysis that controlled for gestational age, no significant differences between the 2 study populations were found for birth weight, gender, visit to child care, presence of older siblings, neurologic disorders, cardiac abnormalities or CLD. There was also no significant difference concerning the risk of RSV-H and ARI-H between children with a GA of 29 to 32 weeks and children with a GA of 33 to 35 weeks.
Neurologic problems (odds ratio ͓OR͔, 3.6; 95% confidence interval ͓CI͔, 1.3-9.9; P ϭ 0.01), male gender (OR, 2.8; 95% CI ϭ 1.6 -5.5; P Ͻ 0.01), presence of an older sibling (OR, 1.7; 95% CI ϭ 1.0 -3.2; P ϭ 0.07) and discharge from October to December (ie, time from Oct. 1 to Dec. 31) (OR, 1.7; 95% CI ϭ 0.9 -3.1; P ϭ 0.09) were independent risk factors for RSV-H in a multivariate analysis. Based on this multivariate logistic regression model (Table  1) , the risk of RSV-H according to combinations of these risk factors was calculated and ranged from 1% (no risk factor present) to 30% (4 risk factors present); different combinations of either 2 or 3 of the risk factors yielded a risk of 4%-12% and 10%-20% RSV-H, respectively.
DISCUSSION
We assessed the risk of RSV-H in a large German-Austrian cohort of preterm children from 29 -35 weeks GA. The incidence of RSV-H found in our study is comparable to similar studies from Canada 4 (RSV-H 3.6% during the first RSV-season; GA 33-35 weeks) and Austria 5 (RSV-H 4.4%; GA 29 -35 weeks). The incidence of RSV-H in children without any of the identified risk factors in our study (1%) is almost equal to the yearly incidence of RSV-H in children Ͻ1 year, regardless of prematurity, as found in a population based study from northern Germany (1.2%). 6 Aside from that, no significant difference concerning the risk of RSV-H and ARI-H was found between children with a GA of 29 to 32 weeks and children with a GA of 33 to 35 weeks. This shows that, in preterm infants of more than 28 weeks of GA, the risk of RSV-H is more dependent on other risk factors than gestational age per se.
We assume that the sum of definite and probable cases in our study approximated the real number of RSV-H. Considering the The Pediatric Infectious Disease Journal • Volume 25, Number 12, December 2006 RSV in Preterms sensitivity of commonly used RSV-antigen tests (44%-91%), negative RSV-tests might have been falsely negative in spite of typical RSV symptoms and a high proportion of RSV in young infants with ARI during the RSV season. 7 The proportion of probable and definite RSV-H in all ARI-H was 52%, which conforms very closely with the reported proportions (50%-63%) in the medical literature. If all children with a negative RSV antigen test were excluded, the overall incidence for RSV-H would have changed only from 4.9% to 4.5%. Four independent risk factors for RSV-H were identified. The presence of a cerebral event during the neonatal period and a subsequent neurodevelopmental handicap during the first 2 years of life were significant risk factors for RSV-H in another cohort study of preterm infants from Austria. 5 Children with a neurologic handicap have an increased risk of developing pulmonary infections caused by repeated aspiration and gastroesophageal reflux, 9 and chronic aspirations are associated with reactive airway disease. 10 Male gender and the presence of 1 or more older siblings were identified as significant independent risk factors for RSV-H in accordance with the medical literature. 1 Young age at the beginning of the RSV season is a consistent risk factor for RSV-H in most studies concerning preterm children, 1 as was also seen in our study (discharge during the time from October to December). Several reasons may account for this: The most severe RSV disease occurs during the first 6 months of life, and children born or discharged during the beginning of the season, rather than during the rest of the year, experience a relatively longer exposure to RSV at a relatively younger chronologic age.
We found 4 independent risk factors that significantly influence the individual risk for severe RSV-disease. Our data show that the risk of RSV-H in preterm children with a GA of 29 -35 weeks and with 3 or more of the risk factors ranges between 10% and 30%. Prophylaxis with palivizumab should be considered in these children because they have a high risk for severe RSV infection, comparable to extremely preterm children (GA Յ28 weeks) and children with CLD, for whom prophylaxis is currently recommended by most guidelines/ advisory boards. In addition, established risk factors derived from literature may be included in a risk score concerning the risk of severe RSV infection in children of comparable preterm populations. The "Estimated risk" was calculated on the basis of a multivariate logistic regression model; the "Actual risk in cohort" is the risk of RSV-H as found in the subgroups of the pooled study population The estimated risk was calculated by: N ontyphoidal Salmonella strains (NTS) are the most common cause of bacteremia in malaria-endemic Africa and a common cause of meningitis and septic arthritis. [1] [2] [3] [4] [5] Previous studies reported NTS bacteremia in African children with a clinical diagnosis of pneumonia, 6, 7 but there is no report from the region that confirms NTS as a cause of pneumonia. We report the novel finding of lobar pneumonia caused by Salmonella typhimurium.
CASE REPORT
A 16 month-old Malawian girl with a 5-day history of fever, cough and dyspnea was admitted to the pediatric research ward at Queen Elizabeth Central Hospital (QECH), Blantyre on February 11, 2006. Two days before admission, she developed poor feeding and irritability. There was no history of diarrhea, vomiting or abdominal pain or of tuberculosis contact.
Relevant history included an admission to the research ward 1 month previously with a diagnosis of cerebral malaria and anemia on the basis of acute fever and convulsions, coma, a positive thick film for Plasmodium falciparum trophozoites and packed cell volume (PCV) of 21%. Cerebrospinal fluid was normal. She was treated with intravenous quinine and oral sulfadoxine-pyrimethamine, regaining full consciousness within 48 hours. PCV fell to 15% on day 3 after admission and was 20% at discharge on day 5. She did not receive a blood transfusion and did not receive antibiotics or iron therapy. Blood culture was negative after 5 days and she was discharged well.
On examination, she was fully alert with weight 8.1 kg, height 70 cm and weight for height of Ͼ85%. She was febrile (axillary temperature 38.6°C) and tachycardic (pulse rate 161 beats/minute) with normal capillary refill and blood pressure. She had marked respiratory distress with a respiratory rate of 80 breaths per minute, nasal flaring, grunting and subcostal indrawing but was not cyanotic. Clinical signs on chest examination were bronchial breathing and coarse inspiratory crackles on auscultation of the left lung consistent with consolidation. The remaining examination was unremarkable. A clinical diagnosis of pneumonia was made and she was treated with 6 mg/kg gentamicin daily and 50,000 IU/kg benzyl penicillin 4 times a day.
Chest radiograph revealed diffuse opacification of the left lung. Blood culture and aspirate of the left lung were taken before starting antibiotics. Thick blood film was negative for malaria parasites and PCV was 23%. Lung aspirate showed a white cell count of 6/mm 3 and 1500/mm 3 red blood cells and no organisms on Gram stain. Repeat chest radiograph postaspiration on day 2 showed complete opacification of the left lung and shift of trachea to the right. Chest ultrasound on day 3 found diffuse homogeneity of the left lung but no visible pleural fluid.
On day 3, she remained unwell, febrile and required oxygen. The antibiotic regimen was changed to 100 mg/kg ceftriaxone per day. Culture of lung aspirate grew S. typhimurium susceptible in vitro to gentamicin, ceftriaxone and ciprofloxacin and resistant to ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole. A tuberculin skin test was nonreactive and 2 rapid HIV tests were negative. Blood culture was negative. By day 2 of ceftriaxone therapy, she had improved, was afebrile and oxygen therapy was discontinued. Ceftriaxone was continued for 7 days followed by 5 mg/kg oral ciprofloxacin twice daily for a further 7 days. At follow up 1 month after discharge, she was well and had a normal chest radiograph.
DISCUSSION
Invasive extraintestinal infections resulting from NTS, usually S. typhimurium and Salmonella enteritidis, are common in tropical Africa and associated with high mortality. [1] [2] [3] At QECH in Blantyre, Malawi, NTS are the most common cause of pediatric bacteremia and septic arthritis and a common cause of meningitis. [3] [4] [5] Although NTS have occasionally been reported elsewhere as a cause of pleuropulmonary disease, especially of empyema in immunocompromised adults, 8, 9 the importance of NTS as a cause of acute bacterial pneumonia in African children is unclear. Studies from the region have shown that NTS is a common isolate, second only to Streptococcus pneumoniae, from the blood of children who have a diagnosis of pneumonia based on clinical findings, 6 ,7 yet studies using lung aspiration in children with acute severe pneumonia have not isolated NTS from the lungs. 10, 11 This case report confirms NTS as a cause of acute community-acquired lobar pneumonia.
This child did not respond to first-line antibiotic therapy. In Malawi and the region of subsaharan Africa, recommended empiric therapy is penicillin for severe pneumonia and chloramphenicol for very severe pneumonia because it is assumed that S. pneumoniae and Haemophilus influenzae are the most common causes. 10, 12 Since the introduction in Malawi of the Hib conjugate vaccine in 2001 and a marked fall in disease resulting from H. influenzae, first-line antibiotics at QECH for invasive bacterial disease in children are aimed primarily at S. pneumoniae and NTS. This includes pneumonia because it is recognized that many children with NTS bacteremia present with clinical features that are consistent with a diagnosis of pneumonia. 1, 2 The in vitro susceptibility profile reported in this case for the S. typhimurium isolate is the same as for approximately 90% of more than 500 NTS isolates from children admitted to QECH since 2001 (S.M. Graham, unpublished data). Penicillin is not active against NTS and failure of chloramphenicol in vivo to treat NTS is now so common at QECH that gentamicin is routinely added to penicillin or chloramphenicol as first-line therapy for pneumonia or suspected septicemia, respectively. Gentamicin was not effective in this case despite in vitro susceptibility possibly because of poor tissue penetration outside the intravascular compartment. Thirdgeneration cephalosporins are not widely available in Malawi but would be preferable as first-line therapy for severe pneumonia as is the case in resource-rich countries.
We included the recent history of an episode of severe malaria with anemia because it is relevant to the presentation of NTS disease. 1, 2 At our hospital, NTS bacteremia and meningitis have been reported to have a strong association with hospitalization for severe malarial anemia in the previous few months compared with other common bacterial pathogens. 13 Most African children with invasive NTS disease are not HIV-infected in contrast to the very strong association with HIV infection in African adults. 1, 2 
